Physician profile
Christopher Eduard Sonntag
NPI 1417454620
$32,469.95
in general payments reported to CMS, 2019-2025
25 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $365 · 2022: $862 · 2023: $2,100 · 2024: $2,619 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $7,675 · Travel and Lodging: $4,237 · Consulting Fee: $1,800 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,425.00 |
| Food and Beverage | $7,675.10 |
| Travel and Lodging | $4,237.15 |
| Consulting Fee | $1,800.00 |
| Education | $106.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24,361.91 | 2021-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $2,098.34 | 2021-2025 | Tremfya |
| Amgen INC. | $1,598.73 | 2022-2025 | Krystexxa, Enbrel, Evenity |
| Glaxosmithkline, LLC. | $758.17 | 2021-2025 | Benlysta, Nucala |
| Ucb, INC. | $642.03 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $478.64 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $417.56 | 2023-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $402.68 | 2023-2025 | Acthar |
| Pfizer INC. | $325.77 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $273.52 | 2022-2025 | Orencia |
| Lilly USA, LLC | $208.99 | 2021-2025 | Taltz |
| Radius Health, INC. | $155.79 | 2022-2025 | Tymlos |
| Fresenius Kabi USA, LLC | $129.39 | 2023-2025 | Idacio, Tyenne |
| Sandoz INC. | $101.24 | 2024-2025 | Hyrimoz |
| Genentech USA, INC. | $98.66 | 2023-2025 | Actemra, Gazyva |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $76.14 | 2025 | Tremfya |
| Alexion Pharmaceuticals, INC. | $63.59 | 2021-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.54 | 2023-2024 | Cyltezo, Ofev |
| Almatica Pharma LLC | $53.58 | 2024 | Teriparatide |
| Horizon Therapeutics Plc | $44.40 | 2023 | Krystexxa |
| Actelion Pharmaceuticals US, INC. | $29.92 | 2024 | Opsumit, Uptravi |
| Ani Pharmaceuticals, INC. | $29.31 | 2025 | Purified Cortrophin Gel |
| Celltrion USA INC. | $23.90 | 2023 | Yuflyma |
| Sobi, INC | $20.98 | 2023 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Sonntag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.